These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
232 related articles for article (PubMed ID: 34592968)
1. Utility of comprehensive genomic profiling in directing treatment and improving patient outcomes in advanced non-small cell lung cancer. Zhao S; Zhang Z; Zhan J; Zhao X; Chen X; Xiao L; Wu K; Ma Y; Li M; Yang Y; Fang W; Zhao H; Zhang L BMC Med; 2021 Oct; 19(1):223. PubMed ID: 34592968 [TBL] [Abstract][Full Text] [Related]
2. Real-World Clinical Outcomes after Genomic Profiling of Circulating Tumor DNA in Patients with Previously Treated Advanced Non-Small Cell Lung Cancer. Olsen S; Liao J; Hayashi H Curr Oncol; 2022 Jul; 29(7):4811-4826. PubMed ID: 35877242 [TBL] [Abstract][Full Text] [Related]
3. Association of Patient Characteristics and Tumor Genomics With Clinical Outcomes Among Patients With Non-Small Cell Lung Cancer Using a Clinicogenomic Database. Singal G; Miller PG; Agarwala V; Li G; Kaushik G; Backenroth D; Gossai A; Frampton GM; Torres AZ; Lehnert EM; Bourque D; O'Connell C; Bowser B; Caron T; Baydur E; Seidl-Rathkopf K; Ivanov I; Alpha-Cobb G; Guria A; He J; Frank S; Nunnally AC; Bailey M; Jaskiw A; Feuchtbaum D; Nussbaum N; Abernethy AP; Miller VA JAMA; 2019 Apr; 321(14):1391-1399. PubMed ID: 30964529 [TBL] [Abstract][Full Text] [Related]
4. ASPiRATION: Australian observational cohort study of comprehensive genomic profiling in metastatic lung cancer tissue. Mersiades AJ; Solomon BJ; Thomas DM; Lee CK; Cummins MM; Sebastian L; Ballinger ML; Collignon E; Turnbull OM; Yip S; Morton RL; Brown C; Wheeler PJ; Itchins M; Simes RJ; Pavlakis N Future Oncol; 2024 Mar; 20(7):361-371. PubMed ID: 37767626 [TBL] [Abstract][Full Text] [Related]
5. Real-world clinical and economic outcomes for patients with advanced non-small cell lung cancer enrolled in a clinical trial following comprehensive genomic profiling via liquid biopsy. Wiedower JA; Forbes SP; Tsai LJ; Liao J; Raez LE J Manag Care Spec Pharm; 2024 Jul; 30(7):660-671. PubMed ID: 38950156 [TBL] [Abstract][Full Text] [Related]
6. Retrospective analysis of real-world data to determine clinical outcomes of patients with advanced non-small cell lung cancer following cell-free circulating tumor DNA genomic profiling. Madison R; Schrock AB; Castellanos E; Gregg JP; Snider J; Ali SM; Miller VA; Singal G; Alexander BM; Venstrom JM; Chung JH Lung Cancer; 2020 Oct; 148():69-78. PubMed ID: 32823229 [TBL] [Abstract][Full Text] [Related]
7. Association of Broad-Based Genomic Sequencing With Survival Among Patients With Advanced Non-Small Cell Lung Cancer in the Community Oncology Setting. Presley CJ; Tang D; Soulos PR; Chiang AC; Longtine JA; Adelson KB; Herbst RS; Zhu W; Nussbaum NC; Sorg RA; Agarwala V; Abernethy AP; Gross CP JAMA; 2018 Aug; 320(5):469-477. PubMed ID: 30088010 [TBL] [Abstract][Full Text] [Related]
9. Genomic Profiling of Advanced Non-Small Cell Lung Cancer in Community Settings: Gaps and Opportunities. Gutierrez ME; Choi K; Lanman RB; Licitra EJ; Skrzypczak SM; Pe Benito R; Wu T; Arunajadai S; Kaur S; Harper H; Pecora AL; Schultz EV; Goldberg SL Clin Lung Cancer; 2017 Nov; 18(6):651-659. PubMed ID: 28479369 [TBL] [Abstract][Full Text] [Related]
10. Real-World Impact of Comprehensive Genomic Profiling on Biomarker Detection, Receipt of Therapy, and Clinical Outcomes in Advanced Non-Small Cell Lung Cancer. Wallenta Law J; Bapat B; Sweetnam C; Mohammed H; McBratney A; Izano MA; Scannell Bryan M; Spencer S; Schroeder B; Hostin D; Simon GR; Berry AB JCO Precis Oncol; 2024 May; 8():e2400075. PubMed ID: 38754057 [TBL] [Abstract][Full Text] [Related]
11. Integration of comprehensive genomic profiling, tumor mutational burden, and PD-L1 expression to identify novel biomarkers of immunotherapy in non-small cell lung cancer. Shi Y; Lei Y; Liu L; Zhang S; Wang W; Zhao J; Zhao S; Dong X; Yao M; Wang K; Zhou Q Cancer Med; 2021 Apr; 10(7):2216-2231. PubMed ID: 33655698 [TBL] [Abstract][Full Text] [Related]
12. Clinical Outcomes for Plasma-Based Comprehensive Genomic Profiling Versus Standard-of-Care Tissue Testing in Advanced Non-Small Cell Lung Cancer. Page RD; Drusbosky LM; Dada H; Raymond VM; Daniel DB; Divers SG; Reckamp KL; Villalona-Calero MA; Dix D; Odegaard JI; Lanman RB; Papadimitrakopoulou VA; Leighl NB Clin Lung Cancer; 2022 Jan; 23(1):72-81. PubMed ID: 34782240 [TBL] [Abstract][Full Text] [Related]
13. Survival Outcomes and Treatment Patterns in Patients With NFE2L2 and/or KEAP1 Mutation-Positive Advanced Squamous Cell NSCLC Using a Real-World Clinico-Genomic Database. Wu Y; Yin Y; Crossland V; Vincent S; Paik PK; Lineberry N; Faller DV Clin Lung Cancer; 2022 Sep; 23(6):487-497. PubMed ID: 35705448 [TBL] [Abstract][Full Text] [Related]
14. Landscape of Biomarkers in Non-small Cell Lung Cancer Using Comprehensive Genomic Profiling and PD-L1 Immunohistochemistry. Huang RSP; Severson E; Haberberger J; Duncan DL; Hemmerich A; Edgerly C; Ferguson NL; Frampton G; Owens C; Williams E; Elvin J; Vergilio JA; Killian JK; Lin D; Morley S; McEwan D; Holmes O; Danziger N; Cohen MB; Sathyan P; McGregor K; Reddy P; Venstrom J; Anhorn R; Alexander B; Brown C; Ross JS; Ramkissoon SH Pathol Oncol Res; 2021; 27():592997. PubMed ID: 34257540 [TBL] [Abstract][Full Text] [Related]